Department of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Int J Cancer. 2022 Jan 15;150(2):327-334. doi: 10.1002/ijc.33802. Epub 2021 Sep 24.
Elevated Epstein-Barr virus (EBV) DNA load is common in lymphomas. However, it remains unclear whether the disparity in viral load and its prognostic value in lymphomas are correlated with Epstein-Barr encoding region (EBER) status. In this retrospective multicenter study, we collected the data of pretreatment whole blood EBV DNA (pre-EBV DNA) and EBER status and evaluated their disparity and prognostic values in lymphomas. A total of 454 lymphoma patients from December 2014 to August 2020 were retrospectively retrieved. Mann-Whitney U test, Kruskal-Wallis test and Bonferroni's adjustment were used to explore the disparity of EBV DNA and EBER status in lymphomas. Time-dependent receiver operating characteristic analysis and MaxStat analysis were used to determine optimal cutoff points of pre-EBV DNA load. Univariable and multivariable Cox proportional hazards models were established for the estimation of prognostic factors. The positive rate of EBV DNA in natural killer T-cell lymphoma (NKTL) patients was higher than that in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) patients, and the median positive pre-EBV copy number of NKTL was also higher than that of FL and DLBCL. EBV DNA could clearly distinguish the prognosis of DLBCL, NKTL, HL and peripheral T-cell lymphoma, and the integration of EBER status and EBV DNA could differentiate the prognosis of HL patients. Multivariable results revealed that pre-EBV DNA load had an effect on the prognosis of NKTL, FL and DLBCL. The status of pre-EBV DNA and EBER were disparate. Whole blood pre-EBV DNA predicted the prognosis of lymphomas, and the combination of EBV and EBER status could differentiate the prognosis of HL.
EBV 病毒(EBV)DNA 载量升高在淋巴瘤中很常见。然而,病毒载量的差异及其在淋巴瘤中的预后价值是否与 EBV 编码区(EBER)状态相关仍不清楚。在这项回顾性多中心研究中,我们收集了治疗前全血 EBV DNA(pre-EBV DNA)和 EBER 状态的数据,并评估了它们在淋巴瘤中的差异及其预后价值。回顾性收集了 2014 年 12 月至 2020 年 8 月间的 454 例淋巴瘤患者的数据。采用 Mann-Whitney U 检验、Kruskal-Wallis 检验和 Bonferroni 调整来探讨 EBV DNA 和 EBER 状态在淋巴瘤中的差异。采用时间依赖性接受者操作特征分析和 MaxStat 分析来确定 pre-EBV DNA 负荷的最佳截断值。建立单变量和多变量 Cox 比例风险模型来评估预后因素。自然杀伤 T 细胞淋巴瘤(NKTL)患者 EBV DNA 的阳性率高于弥漫性大 B 细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)和霍奇金淋巴瘤(HL)患者,NKTL 的中位 EBV DNA 阳性拷贝数也高于 FL 和 DLBCL。EBV DNA 可清楚地区分 DLBCL、NKTL、HL 和外周 T 细胞淋巴瘤的预后,EBER 状态和 EBV DNA 的整合可区分 HL 患者的预后。多变量结果显示,pre-EBV DNA 负荷对 NKTL、FL 和 DLBCL 的预后有影响。pre-EBV DNA 和 EBER 的状态存在差异。全血 pre-EBV DNA 可预测淋巴瘤的预后,EBV 和 EBER 状态的结合可区分 HL 的预后。